FAQ


Contact Us | LogIn     
Search
1546-2080 Online :: 1546-203X Print
Case Study: Arrowhead’s Acquisition of Roche’s siRNA Delivery Technology Platform
Volume 8, Issue 4


Authors:
John Miller

Abstract:
In fall 2011, Arrowhead Research Corporation announced that it had acquired Roche’s RNA interference (RNAi) business previously known as Roche RNA Therapeutics. In this article, Nanotechnology Law & Business Managing Editor John Miller reviews the structure of the transaction, provides an overview of the technology, and explains why this deal is likely to have a major impact on Arrowhead’s future as well as the future of siRNA.

Full Text (PDF)
Home   :   Aims & Scope    :   Editorial Board    :   Subscriptions   :   Partnerships  :   Disclaimer  :   Contact Us
Nanotechnology Law & Business Copyright 2005